NC
SMMT icon

NewSquare Capital’s Summit Therapeutics SMMT Stock Holding History

NewSquare Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-230
Closed -$577 – 860
2023
Q2 		$577 Hold
230
– – ﹤0.01% 669
2023
Q1 		$403 Hold
230
– – ﹤0.01% 733
2022
Q4 		$978 Buy
+230
New +$418 ﹤0.01% 575

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

NewSquare Capital's SMMT Position: Q3 2023 in Review

NewSquare Capital sold out of Summit Therapeutics (SMMT) in Q3 2023, closing a stake of 230 shares — an estimated $577 sold.

NewSquare Capital first reported a position in SMMT in Q4 2022 and held it in 3 quarters. The position peaked at $978 in Q4 2022. 93 funds tracked by Wall St. Rank hold SMMT as of Q3 2023.

  • NewSquare Capital reported no remaining Summit Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 230 Summit Therapeutics shares in Q3 2023, an estimated $577.
  • NewSquare Capital first reported a position in Summit Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Summit Therapeutics position peaked at $978 in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.